PORTLAND, Ore., Jan. 4 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, today announced that the National Institutes of Health
("NIH") is utilizing the Biojector(R) 2000 ("B2000") in its first human
trial of a DNA vaccine designed to prevent H5N1 avian influenza infection.
The vaccine was administered to the first volunteer a few weeks ago at the
NIH clinical center in Bethesda, MD.
The study will enroll 45 volunteers between the ages of 18 and 60.
Fifteen will receive placebo injections and 30 will receive three
injections of the investigational vaccine over two months and will be
followed for one year. Volunteers will not be exposed to influenza virus.
"We're pleased to be working with the NIH and for it choosing our
needle free injection technology for such an important clinical study and
the advancement in medicine. It is a clinical advantage to be able to offer
this vaccine with a needle free delivery system thus making it safer for
patients and clinicians. We have found that it may potentially provide a
therapeutic benefit from improved immunogenicity as we have seen with other
vaccines," said Richard R. Stout M.D., Vice President Clinical Affairs at
Bioject. "The NIH is also using the B2000 needle free system with its DNA
HIV vaccines that are currently in clinical trials throughout the world."
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of
high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary
companies.
For more information on Bioject, visit http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
Chris Farrell, Vice President of Finance,
+1-503-692-8001, ext. 4132, or Dr. Richard Stout, Vice President
of Clinical Affairs, +1-503-692-8001, ext. 4130, both of Bioject
Medical Technologies Inc.
|
